Maria João Cardoso, MD, PhD

Similar documents
ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

Point of view of the surgeons

Pregnancy in the middle of adjuvant treatment of Her2 positive breast cancer

So, we already talked about that recognition is the key to optimal treatment and outcome.

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy

National Breast Cancer Audit next steps. Martin Lee

Evaluation of the Axilla Post Z-0011 Trial New Paradigm

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center

Diagnosis and staging of breast cancer and multidisciplinary team working

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes

Breast Cancer Breast Managed Clinical Network

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Breast Cancer. Saima Saeed MD

ARROCase - April 2017

3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Breast Cancer. Pathologic Staging Updates Breast Cancer

PET/CT in breast cancer staging

How can surgeons help the Radiation Oncologists?

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

Enterprise Interest None

Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)

Breast Cancer Diagnosis, Treatment and Follow-up

CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?

Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Barlavento Medical Centre - Portimão, Portugal

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Surgery for Breast Cancer

Evolution of Breast Surgery

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.

Tata Memorial Centre s opinion is summarized as follows:

National Center of Oncology - Yerevan, Armenia

Clinical Management Guideline for Breast Cancer

Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options

Locally advanced BC: radiation therapy

M D..,., M. M P.. P H., H, F. F A.. A C..S..

ACRIN 6666 Therapeutic Surgery Form

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Guideline for the Management of Vulval Cancer

Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery

clear evidence of the signs and symptoms of infection, simply a breast cancer that looks like infection.

When do you need PET/CT or MRI in early breast cancer?

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham. Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence

Recent Update in Surgery for the Management of Breast Cancer

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Breast cancer: an update

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection

Interactive Staging Bee

Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

Breast Unit - University of Heidelberg - Heidelberg, Germany

Neoadjuvant (Primary) Systemic Therapy

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

RADIOTHERAPY IN BREAST CANCER :

Sheri Saluga A/P 2 May 1, Breast Cancer

Classification System

Mammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand

Lecture 5. Primary systemic therapy: clinical and biological endpoints

University Clinical Center Banja Luka, Breast Center - Banja Luka, Bosnia and Herzegovina

How is primary breast cancer treated?

NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE

ESSO ACCREDITED TRAINING FELLOWSHIP IN BREAST SURGERY

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Loco-Regional Management After Neoadjuvant Chemotherapy

Seventh Edition Staging 2017 Breast

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Tata Memorial Hospital - Mumbai, India

RUTGERS CANCER INSTITUTE OF NEW JERSEY - ROBERT WOOD JOHNSON MEDICAL SCHOOL INTERDISCIPLINARY BREAST SURGERY FELLOWSHIP CORE EDUCATIONAL OBJECTIVES

Loco-Regional Management After Neoadjuvant Chemotherapy

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

General Surgery Curriculum Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons

Detailed Program of the second BREAST IMAGING AND INTERVENTIONS PROGRAM am am : Clinician s requirements from breast imaging

Joint ASPS & ASAPS Statement on Breast Implant Associated ALCL

Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer

STAGE CATEGORY DEFINITIONS

Breast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland

Node nega)ve breast cancer: Immediate breast reconstruc)on - An op)on for every pa)ent? Peer Chris)ansen

Breast Clinica de la Mama and Italian Hospital - La Plata, Argentina

Cancer Endorsement Maintenance 2011-Maintenance Measures

It is a malignancy originating from breast tissue

Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018)

Cases presented with teleradiology and telepathology by the local team

Cancer Program Report 2014

Ultrasound or FNA for Predicting Node Positive in Breast Cancer

Clinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair

Ductal Carcinoma in Situ (DCIS)

Presented by: Lillian Erdahl, MD

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP

Advances in Localized Breast Cancer

Transcription:

Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1

Conflict of Interest Disclosure No financial relationships to disclose 2

Dealing with different locorregionalpresentation and different biology Nat Rev ClinOncol. 2015 Mar;12(3):147-62. Management of locally advanced breast cancer-perspectives and future directions. Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. 3

Heterogeneity of LABC in staging Breast cancer >5 cm, Four or more pathologically involved axillary nodes in the axilla, IM or IC/SC, Disease extending to the chest wall or skin (T4), Inflammatory breast cancer (T4d) 4

Stage IIB Stage IIIA N0 T3 N1 N1 T3 Heterogeneity of LABC N2 T1-3 5

Stage IIIB N0 T4 N1 T4 N1 N2 T4 N2 Stage IIIC N3 Heterogeneity of LABC 6

Locorregional approach Operable Inoperable Inflammatory 7

ABC STATEMENTS FOR LABC For the purpose of these recommendations, LABC means INOPERABLE, NON-METASTATIC LOCALLY ADVANCED BC 8

LOCALLY ADVANCED INOPERABLE BC (LABC) BEFORE starting any therapy, a core biopsy providing histology and biomarker (ER, PR, HER-2, proliferation/grade) expression is indispensable to guide treatment decisions.(loe: I B) (97%) Since LABC patients have a significant risk of metastatic disease, a full staging workup, including a complete history, physical examination, lab tests and imaging of chest and abdomen (preferably CT) and bone, prior to initiation of systemic therapy is highly recommended. (LoE LoE: I B) (100%) PET-CT, if available, may be used (instead of and not on top of CTs & bone scan). (LoE LoE: II B) (100%) 9

LOCALLY ADVANCED INOPERABLE BC (LABC) Systemic therapy (not surgery or RT) should be the initial treatment. If LABC remains inoperable after systemic therapy and eventual radiation, palliative mastectomy should not be done, unless the surgery is likely to result in an overall improvement in quality of life. (LoE: Expert opinion) (100%) A combined treatment modality based on a multidisciplinary approach (systemic therapy, surgery and radiotherapy) is strongly indicated in the vast majority of cases. (LoE LoE: I A) (100%) 10

11

Level of evidence????? (MDT) expert opinion 12

Objectives Conversion of patients with inoperable tumors to operable Local control of disease aiming at the highest possible QOL 13

Evaluation prior to primary systemic therapy for LABC Natural history of the disease (rapid growing <6 months versus neglected tumours) Clinical examination: -Clinical size of tumor -Skin changes: erythema, edema, ulceration, and dimpling -Lymph node status (imaging) Photo documentation (inflammatory, T4 s ) 14

Evaluation prior to primary systemic therapy for LABC Pathology: CORE BIOPSY! -FNA cytology is not acceptable anymore! (except for N disease) -Full assessment of grade, invasion (LV), ER, PR, Her2, Ki67 Adequate local breast imaging: extent of disease breast and axilla -Mammography very informative in IBC -Ultrasound for T and mostly N -MRI important when aiming at a possible BCT and when other forms are non-informative Clip/Tattoing placement at dg(for surgery & pathology!) Staging: X-ray, blood tests (CBC, liver, AP) bone scan, abdominal IBC Punch biopsies????(high number of false negatives) 15

Should always be an MDT decision Before starting treatment and much more frequently evaluated 16

Ten years passed but the rational stays the same except for the addition of anti Her2 therapies or new drugs in a clinical trial setting. There is howeverno answer for the minority of those that in the end still have no response. Update on LABC, Giordano 2003 The Oncologist 2003; 8:521-530 17

Surgery after primary chemotherapy / radiotherapy Type of surgery -MRM for all LABC?! Criteria for breast conservation ( Singletary, Cancer Treat Res 1997) -Resolution of skin edema -Residual tumor size <5 cm -Absence of extensive breast lymphatic invasion -Absence of extensive suspicious microcalcifications->mrm -No evidence of multicentricity-> MRI -Tumor biology? (more local recurrences) 18

The importance of an accurate initial assessment of the extent of primary tumor burden cannot be overemphasized since the efficacy of subsequent local treatment will depend mostly on this initial assessment. 19

Criteria for mastectomy IBC Persistence of skin edema Residual tumor size > 5 cm (Oncoplastic techniques) Presence of extensive suspicious microcalcifications- >mammography, MRI Evidence of multicentricity-> MRI Tumor biology???(radioresistent tumors) 20

If mastectomy Immediate or Delayed Breast Reconstruction Not IBR if IBC If local control is not attained and the intention is tumor debulkingunless reconstruction to cover large skin defects in extreme cases Radiotherapy will almost always be used Avoid implant based reconstruction Reconstruction before or after radiotherapy (no difference in Cosmetic Outcome LoE: III) 21

Local recurrence in LD autologusflap IBR in IBC 22

23

80, HR +++, Her2 negative, Grade 1 Abandoned advanced breast cancer in an old patient: A difficult challenge Cardoso MJ, Valente F, Lima LM, Ferreira S, Costa E, de Oliveira MC, Ferreira P, Cardoso A, Amarante JM BREAST JOURNAL 2005. VL 11; IS 2:151-152 24

LABC Clinical/US N0 Disease Pre-treatment SNB and post treatment SNB in inoperable LABC (T4) even with N0 (clinical and US) axilla should not be standard of care. Clinical significance of a false negative SLN more relevant as the denominator of node positive patients becomes larger What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer? C. Cox et al. Current Oncology Volume 20, Number 2, April 2013 25

LABC Clinical/US N positive Disease Any patient found to have N2 or N3 nodal metastases by any technique, pre- or post-chemotherapy, should receive a completion axillary node dissection Current data are insufficient to identify patients who do not need axillary specific treatment in inoperable LABC IBC should always receive standard axillary dissection 26

Conclusions: Treatment of inoperable LABC should always be an MDT decision Every member of the team involved in clinical evaluation during treatment ( if disease progresses in spite of everything at some point tumour resection debulking- if possible, may be useful to improve QOL. BCT is option in highly selected patients When immediate reconstruction is considered: count on radiotherapy before choosing the technique and decide timing 27

Conclusions : IBC should be surgically treated with Mastectomy and axilalary dissection Delay reconstruction in IBC and in LABC non inflammatory, when you think it will pose problems in timing or planning of radiotherapy For the time being treat the axilla as positive 28

29